Polydatin (Piceid)

Polydatin (3,4',5-trihydroxystilbene-3-beta-D-glucopyranoside), also designated piceid, is a stilbene glucoside and the most abundant naturally occurring glycosylated form of resveratrol. The compound is principally isolated from the roots and rhizomes of Polygonum cuspidatum Sieb. et Zucc. (Reynoutria japonica, Japanese knotweed), a plant with extensive documentation in traditional Chinese and Japanese pharmacopeias, and is additionally present in grapes (Vitis vinifera), peanuts (Arachis hypogaea), hop cones (Humulus lupulus), red wines, and cocoa-containing products. The glucose moiety at the C-3 position of the stilbene backbone confers critical pharmacokinetic advantages over the aglycone resveratrol: active intestinal absorption via the sodium-dependent glucose cotransporter SGLT1 (rather than passive diffusion), oral bioavailability estimated at approximately 80 percent versus less than 20 percent for resveratrol, a longer plasma half-life of approximately 4 to 6 hours versus 1 to 2 hours for resveratrol, and enhanced resistance to rapid Phase II conjugative metabolism that limits the systemic exposure achievable with resveratrol administration.

The molecular pharmacology of polydatin is pleiotropic and converges on several well-characterized intracellular signaling cascades. The compound is a direct activator of sirtuin 1 (SIRT1), the NAD-dependent protein deacetylase that regulates mitochondrial biogenesis, cellular stress resistance, and inflammatory gene expression through downstream effectors including peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), forkhead box O transcription factors, and p53. Polydatin activates AMP-activated protein kinase (AMPK), a central metabolic sensor that suppresses anabolic pathways and promotes catabolic energy production under conditions of cellular energy deficit. Through SIRT1 and AMPK convergence, polydatin induces the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway, upregulating heme oxygenase-1 (HO-1), superoxide dismutase, catalase, and glutathione peroxidase expression. Concurrently, polydatin suppresses nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) nuclear translocation and downstream proinflammatory cytokine production (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6), inhibits the NLRP3 inflammasome, and modulates the PI3K/Akt and MAPK (ERK, p38, JNK) signaling axes. The compound also inhibits Lyn and Syk kinase activity in mast cell degranulation pathways and modulates mitochondrial dynamics through suppression of dynamin-related protein 1 (Drp1) expression.

Preclinical pharmacology spans cardiovascular protection (myocardial ischemia-reperfusion injury, hemorrhagic shock, septic shock), neuroprotection (ischemic stroke, Parkinson's disease, Alzheimer's disease, traumatic brain injury, diabetic neuropathy), hepatoprotection (nonalcoholic steatohepatitis, carbon tetrachloride-induced fibrosis, alcoholic liver disease), nephroprotection (diabetic nephropathy, cisplatin-induced and ischemia-reperfusion-induced acute kidney injury), anti-neoplastic activity (breast cancer, osteosarcoma, oral squamous cell carcinoma, acute myeloid leukemia, multiple myeloma, hepatocellular carcinoma), anti-inflammatory and immunomodulatory effects (colitis, acute lung injury, allergic inflammation, osteoarthritis), and metabolic regulation (diabetes, obesity, hyperlipidemia). The compound crosses the blood-brain barrier, a property critical to its neuroprotective applications.

Clinical evidence is limited relative to the breadth of preclinical data. Polydatin injectable (100 mg/5 mL) has been evaluated in a Phase II clinical trial (NCT01780129) for traumatic/hemorrhagic shock and septic shock. Oral polydatin has been studied as a combination component with palmitoylethanolamide (PEA/polydatin, 400 mg/40 mg in the published literature) in irritable bowel syndrome and chronic pelvic pain related to endometriosis, with safety profiles similar to placebo over 12-week treatment periods. Formal registration as a single-entity therapeutic agent has not been achieved in major Western regulatory jurisdictions. The compound is classified as "possibly marketed outside the United States" (NCATS Inxight Drugs) and is available as a research-grade preparation from multiple chemical suppliers at greater than 95 percent purity. This monograph reviews the chemistry, natural source pharmacognosy, multi-target molecular pharmacology, pharmacokinetics and bioavailability comparison with resveratrol, the preclinical evidence base across organ systems, the limited clinical evidence, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event signal, and a comparative assessment of five stilbene and polyphenol research compounds against polydatin on five competency standards.